Articles tagged with Immunotherapy
A new Cochrane Systematic Review finds sublingual immunotherapy significantly reduces symptoms of allergic rhinitis and medication requirements. The treatment has very few serious adverse effects and is effective in children, offering a convenient alternative to injection immunotherapy.
Researchers propose new clinical trial endpoints for immunotherapies, accounting for delayed responses and novel patterns of anti-tumor activity. The immune-related response criteria (irRC) offer a revised approach to measuring treatment success, considering factors such as lymphocyte infiltration and tumor burden.
Researchers have identified three protein fragments in gluten that trigger an immune response in people with coeliac disease, leading to small intestine damage. This discovery could pave the way for a new generation of diagnostic tools, treatments, and prevention strategies.
A preclinical study suggests combining targeted therapy against the BRAF/MAPK pathway with immunotherapy may improve durability of responses in treating melanoma. Researchers found that inhibiting the MAPK pathway resulted in increased antigen expression, leading to improved recognition by T-cells.
Researchers at Yale University found that carbon nanotubes cause T cell antigens to cluster in high concentrations, stimulating the body's natural immune response. This breakthrough could improve current adoptive immunotherapy for cancer treatment by increasing T cell proliferation.
The study demonstrates a potential new treatment paradigm in oncology with improved overall survival rates for metastatic castration-resistant prostate cancer patients. The treatment, Sipuleucel-T, was shown to have well-balanced prognostic factors and mild adverse events.
A new study suggests that stimulating human lung cancer cells with TLR7 or TLR8 agonists can lead to increased tumor cell survival and resistance to chemotherapy. This approach is being investigated as an adjuvant for anticancer immunotherapies, but caution should be exercised due to these potential risks.
Researchers at Johns Hopkins Children's Center report encouraging results in children with egg allergies who consume increasingly higher doses of egg protein. The study found that more than half of the children could tolerate 5 grams of eggs without an allergic reaction, experiencing mild to moderate symptoms.
The Phase 3 IMPACT trial found that sipuleucel-T significantly prolonged overall survival by 4.1 months and improved three-year survival by 38 percent compared to placebo. This innovative immunotherapy reduced the risk of death by 22.5 percent.
Researchers found that gradually increasing doses of milk protein over time can help children with severe and persistent milk allergy tolerate the allergen, reducing symptoms and building tolerance. The study suggests oral immunotherapy may be a promising treatment option for food allergies.
Researchers at the University of Montreal and Argos Therapeutics have developed a novel method to create personalized immunotherapy treatments for HIV. The treatment uses dendritic cell-based therapies that stimulate the expansion of HIV-specific T cells, which attack and kill infected cells.
Researchers found that standard flu vaccine boosted immune function in patients with recurrent or metastatic Ewing's sarcoma and alveolar rhabdomyosarcoma, leading to higher five-year overall survival rates. The study suggests immunotherapy could be beneficial for high-risk pediatric sarcomas.
Researchers have developed a new immunotherapy technique called OPAL therapy that stimulates immunity and controls virus levels in HIV-infected individuals. The treatment involves reinfusing fresh blood cells with overlapping peptides, showing promise in preventing AIDS progression.
A six-week experimental allergy treatment has relieved hay fever symptoms for at least two years in a clinical trial. The novel DNA-based drug AIC blocks the seasonal rise in ragweed-specific IgE and reduces IL-4, hinting at successful immune system reprogramming.
Researchers found that children who received venom allergy shots had significantly fewer life-threatening reactions when restung, even years later. Dr. Rebecca Gruchalla recommends the shots for kids with severe allergic reactions to insect stings, which are responsible for at least 40 fatal stings per year.
A study found that children who received venom immunotherapy for moderate to severe allergic reactions had a lower risk of future reactions, including those with no prior treatment. The therapy was shown to last for up to three and a half years, making it an effective long-term solution for managing bee sting allergies.
A randomized clinical trial showed that adjuvant chemotherapy and immunotherapy for colon cancer patients offer no disease-free or overall survival benefits after 10 years. The improvements in 5-year survival rates observed in the past have disappeared over time, suggesting that newer chemotherapy regimens may be more effective.
IVIg is the preferred treatment for Guillain-Barré Syndrome due to its ease of use and lower complication rate compared to plasma exchange. Early treatment within two weeks of symptom onset improves chances for a better outcome.
Researchers investigating a potential new treatment for type 1 diabetes found severe allergic reactions in mice, raising concerns about its safety. The study's findings contrast with earlier mouse studies suggesting the treatment could reduce incidence of diabetes, and highlight the need for cautious evaluation of immunotherapy research.
Researchers at the University of Melbourne have developed a potential allergy vaccine using a modified rye grass protein that reduces allergenic response while boosting immune system. The vaccine, delivered in its pure form, may significantly reduce risk of anaphylactic shock and increase immunotherapy efficacy.
Researchers found that rush immunotherapy targeting a single allergen makes distinct changes in T cells and prevents allergic reactions. The study showed that T cells produce more interferon gamma, an element that lowers allergic responses, and shut off production of pro-allergic cytokines.